Abdul Baig

Dr. Abdul Baig


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
ABAbdul Baig
Abdul Baig
AKAreeba Khaleeq
Areeba Khaleeq
UAUsman Ali
Usman Ali
HSHira Syeda
Hira Syeda
The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and has evoked a scare of epic proportion regarding its potential to spread and infect humans worldwide. As we are in the midst of an ongoing pandemic of COVID-19, scientists are struggling to understand how it resembles and differs from the severe acute respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic level. In a short time following the outbreak, it has been shown that, similar to SARS-CoV, COVID-19 virus exploits the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the cells. This finding raises the curiosity of investigating the expression of ACE2 in neurological tissue and determining the possible contribution of neurological tissue damage to the morbidity and mortality caused by COIVD-19. Here, we investigate the density of the expression levels of ACE2 in the CNS, the host–virus interaction and relate it to the pathogenesis and complications seen in the recent cases resulting from the COVID-19 outbreak. Also, we debate the need for a model for staging COVID-19 based on neurological tissue involvement.

7 April 2020 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
ABAbdul Baig
Abdul Baig
Click on the book chapter title to read more.

23 October 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
ABAbdul Baig
Abdul Baig
With the ongoing pandemic of coronavirus diseases (COVID‐19) caused by SARS‐CoV‐2, there has been a surge in research and publications related to its pathogenesis and the clinical presentation of the affected patients. Many aspects of this novel virus have raised confusion including the naming of the virus and the disease it causes, the staging of its clinical presentation to highlight a few such occurrences. An emerging aspect of the clinical presentation related to COVID‐19 is the long‐term effects, which in the absence of any consensus has been termed as long‐covid and long‐haulers in recent publications. As the COVID‐19 is a zoonotic infection and comes under a medically related disease, the term chronic covid syndrome (CCS) would be a more traditional way of symbolizing the so‐called long‐covid and long‐haulers in COVID‐19. Though the renaming of this chronic state of now well‐recognized chronicity seen in COVID‐19 would not affect its prognosis, this is much needed to recognize this entity with a more appropriate nomenclature as published work is making its way into databases like Google Scholar and PubMed.



1 August 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ABAbdul Baig
Abdul Baig
JIJunaid Iqbal
Junaid Iqbal
Naveed Ahmed KhanNaveed Ahmed Khan
Naveed Ahmed Khan
The effects of clinically available drugs targeting muscarinic cholinergic, adrenergic, dopaminergic, and serotonergic receptors; intracellular calcium levels and/or the function of calcium-dependent biochemical pathways; ion channels; and cellular pumps were tested against a keratitis isolate of Acanthamoeba castellanii belonging to the T4 genotype. In vitro growth inhibition (amoebistatic) assays were performed by incubating A. castellanii with various concentrations of drugs in the growth medium for 48 h at 30°C. To determine amoebicidal effects, amoebae were incubated with drugs in phosphate-buffered saline for 24 h, and viability was determined using trypan blue exclusion staining. For controls, amoebae were incubated with the solvent alone. Of the eight drugs tested, amlodipine, prochlorperazine, and loperamide showed potent amoebicidal effects, as no viable trophozoites were observed (>95% kill rate), while amiodarone, procyclidine, digoxin, and apomorphine exhibited up to 50% amoebicidal effects. In contrast, haloperidol did not affect viability, but all the drugs tested inhibited A. castellanii growth. Importantly, amlodipine, prochlorperazine, and loperamide showed compelling cysticidal effects. The cysticidal effects were irreversible, as cysts treated with the aforementioned drugs did not reemerge as viable amoebae upon inoculation in the growth medium. Except for apomorphine and haloperidol, all the tested drugs blocked trophozoite differentiation into cysts in encystation assays. Given the limited availability of effective drugs to treat amoebal infections, the clinically available drugs tested in this study represent potential agents for managing keratitis and granulomatous amoebic encephalitis caused by Acanthamoeba spp. and possibly against other meningoencephalitis-causing amoebae, such as Balamuthia mandrillaris and Naegleria fowleri .